loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Krsnaa Diagnostics Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Krsnaa Diagnostics Ltd. 10 Nov 2025 12:48 PM
Result PDF

Q2FY26 Quarterly Result Announced for Krsnaa Diagnostics Ltd.

Healthcare Services company Krsnaa Diagnostics announced Q2FY26 results

  • Revenue from Operations: Rs 2,060 million compared to Rs 1,863 million during Q2FY25, change 11%.
  • EBITDA: Rs 602 million compared to Rs 509 million during Q2FY25, change 18%.
  • EBITDA Margin: 29% for Q2FY26.
  • PAT: Rs 239 million compared to Rs 196 million during Q2FY25, change 22%.
  • PAT Margin: 12% for Q2FY26.
  • EPS: Rs 7.25 for Q2FY26.

Yash Mutha, Managing Director, said: “Krsnaa Diagnostics has delivered its highest-ever quarterly profit, reinforcing the strength and resilience of our business model. Revenue grew 12% YoY in H1FY26, driven by expanding patient volumes and the growing confidence in our diagnostic network across India. EBITDA increased 18% YoY to Rs 1,126 million, with margins improving to 28%, reflecting disciplined execution and strong operating leverage. Net profit rose 19% to Rs 445 million, underscoring our focus on profitable and sustainable growth.

Over the years, we have built one of India’s most efficient and inclusive diagnostic platforms, with a presence across Tier-II and Tier-III markets through our Public-Private Partnership model. This structure not only supports volume growth but also provides stability through long-term contracts and broad geographic diversification.

On the working capital side, our receivable cycle currently stands around 150 days, reflecting a temporary transition linked to new central government payment norms under which states are aligning to RBI-linked disbursement mechanisms. Furthermore, Krsnaa has not recorded any bad debts since inception, underscoring the quality of our receivables and the credibility of our government partnerships.

Our focus remains on accelerating collections, optimizing cash flows, and reinvesting into high-impact growth initiatives such as the Rajasthan PPP — India’s largest diagnostic project — which is progressing well and on schedule. With multiple labs going live in the coming months, we anticipate meaningful revenue contribution starting Q4FY26 and a full-year impact in FY27.

With strong fundamentals, disciplined execution, and a clear growth roadmap, Krsnaa is well-positioned to deliver sustainable value and reinforce its leadership in India’s diagnostics landscape.”

Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics, we remain steadfast in our commitment to quality, integrity, and patient-centric care. Leveraging our Public-Private Partnership (PPP) model, we provide free and high-quality diagnostic services across India, enabling millions to access essential healthcare. Our pan-India network and close collaboration with state governments have firmly established Krsnaa as a trusted and preferred partner in public healthcare delivery.

We are delighted to announce that for the first time in India, our company has received accreditation from the American College of Radiology (ACR) — a prestigious milestone marking the first-ever ACR recognition outside the United States. This global distinction stands as a testament to Krsnaa’s unwavering pursuit of excellence and adherence to international standards in imaging and radiology. Additionally, we are also proud to continue holding the CAP (College of American Pathologists) accreditation, the only such recognition granted to a government diagnostic location in India.

These dual international accreditations underscore our relentless focus on quality, precision, and patient safety. They reaffirm Krsnaa’s position as a benchmark for globally recognized diagnostic standards in India, strengthening our reputation among clinicians, government partners, and patients alike. Importantly, these achievements also contribute to higher patient trust, improved volumes, and stronger institutional credibility, supporting long-term growth.

Recently, we were honoured with the title of “India’s Most Trusted Integrated Diagnostic Brand” at the Big FM – Big Impact Awards held in Vietnam, a testament to our unwavering commitment to quality, accessibility, and patient trust

With a foundation built on internationally accredited quality, a scalable nationwide platform, and a clear mission to make advanced diagnostics accessible to all, Krsnaa Diagnostics is well-positioned to capitalize on India’s expanding healthcare landscape, drive sustainable growth, and enhance value for all stakeholders.”

Result PDF

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q1FY26 results

  • Revenue from Operations: Rs 1,930 million compared to Rs 1,702 million during Q1FY25, change 13%.
  • EBITDA: Rs 524 million compared to Rs 442 million during Q1FY25, change 19%.
  • EBITDA Margin: 27% for Q1FY26.
  • PAT: Rs 205 million compared to Rs 179 million during Q1FY25, change 15%.
  • PAT Margin: 11% for Q1FY26.
  • EPS: Rs 6.25 for Q1FY26.

Yash Mutha, Managing Director, said: “We are delighted to share that Krsnaa Diagnostics has been awarded one of the most prestigious and transformative healthcare projects in the state of Rajasthan under the National Health Mission (NHM). After being on hold for some time, this critical project is now set in motion. This landmark initiative will enable us to deliver best-in-class diagnostic services to millions of citizens across the state, reinforcing our mission of making quality healthcare accessible to all.

As part of this project, we will establish 42 state-of-the-art Mother Labs, 135 Satellite Labs, and over 1,300 Collection Centres, making it one of the largest and most comprehensive PPP diagnostic projects ever undertaken in India. The scale, reach, and impact of this tender underscore not just the trust placed in Krsnaa Diagnostics but also our proven ability to execute large-scale public health initiatives with excellence.

It marks a defining growth milestone, one that will drive both strategic expansion and long-term value creation while making a meaningful difference in public health delivery.

In Q1FY26, Krsnaa delivered a remarkable 13% YoY revenue growth, reaching Rs 1,930 million, driven by rising patient trust and growing brand awareness. Krsnaa Diagnostics has delivered breakout retail growth a 7.9x jump in revenue and a 6.7x surge in touchpoints in just 12 months, now spanning 2,414 locations across four states, we are fast emerging as India’s most formidable retail diagnostics growth story. Our services continue to gain traction, with significant increases in test volumes and patient footfall. EBITDA surged 19% YoY to Rs 524 million, supported by healthy margin expansion to 27%. Net profit climbed 15% YoY to Rs 205 million, with margins improving to 11% a reflection of our disciplined execution, operational efficiencies, and the strategic rollout of new centres. This consistent performance is a testament to our scalable model, strong governance, and operational agility, which position us to thrive in an evolving and high-growth healthcare ecosystem.

Looking ahead, we are more energised and optimistic than ever. Backed by a seasoned and deeply committed leadership team, we are:

  • Aggressively pursuing high-potential tenders across multiple states.
  • Expanding into new geographies, through both PPP and our fast-growing RPL retail vertical.
  • Strengthening our project pipeline to ensure sustained, predictable growth momentum.

We are also making strategic investments in technology, automation, and digital transformation, unlocking faster turnaround times, seamless patient experiences, and future-ready operations. At Krsnaa Diagnostics, we are building more than a business; we are creating a healthcare movement that empowers communities, strengthens public health infrastructure, and generates long-term value for all stakeholders.”

Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics Limited, we remain unwavering in our mission to transform India’s diagnostic landscape by making high-quality, affordable, and technology-enabled diagnostic services available to every Indian regardless of geography, income, or infrastructure barriers.

Diagnostics today are not just a support function in healthcare; they are the bedrock of effective treatment and prevention. With every test we perform, we enable quicker diagnoses, better outcomes, and healthier lives. And we take immense pride in being at the forefront of this transformation, not just participating in the growth of the industry, but leading it.

It is with great pride and optimism that I share a landmark development in our growth journey, the successful execution of the Rajasthan Pathology tender agreement, one of the largest and most strategically significant public healthcare projects in India. This is healthcare infrastructure transformation at a population scale. It is a bold demonstration of Krsnaa’s unmatched execution capability, speed of deployment, and expertise in navigating complex healthcare ecosystems. With this project, we will touch millions of lives, enabling timely, affordable diagnostics in every corner of Rajasthan. The significance of this win goes far beyond numbers:

  • It cements our leadership position in large-scale Public-Private Partnerships.
  • It showcases our ability to build state-wide networks with speed, efficiency, and clinical excellence.
  • It further validates the trust governments place in Krsnaa as their implementation partner of choice.

This strategic milestone also significantly strengthens our long-term growth outlook. Our presence across Rajasthan is now comprehensive and deep-rooted, forming a robust platform for further expansion both in public healthcare and our fast-growing RPL retail brand.

These initiatives are not just about expansion; they are about creating real impact. Whether it's through Public-Private Partnerships (PPP), state healthcare tenders, or direct-to-patient retail offerings under our RPL brand. We have consistently demonstrated our ability to deliver timely, technology-enabled, and patient-centric diagnostic solutions across urban, semi-urban, and rural India.

As we continue to scale and deepen our presence, our core purpose remains unchanged: To be India’s most trusted and preferred diagnostics partner, delivering care that is affordable, dependable, and always within reach.

We are excited about what lies ahead. With the Rajasthan project in motion, a strong national pipeline, and growing traction in both PPP and retail, Krsnaa Diagnostics is entering a new phase of accelerated, high-impact growth. And we are confident that we will continue to deliver long-term value to our patients, partners, and investors alike.”

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from Operations: Rs 1,861 million vs Rs 1,663 million in Q4FY24 (Change: 12%)
  • Other Income: Rs 44 million vs Rs 43 million in Q4FY24
  • Total Income: Rs 1,905 million vs Rs 1,706 million in Q4FY24 (Change: 12%)
  • EBITDA: Rs 542 million vs Rs 441 million in Q4FY24 (Change: 23%)
  • EBITDA Margin: 29% vs 27% in Q4FY24
  • EBIT: Rs 354 million vs Rs 299 million in Q4FY24 (Change: 18%)
  • EBIT Margin: 16% vs 18% in Q4FY24
  • Profit After Tax (PAT): Rs 207 million vs Rs 187 million in Q4FY24 (Change: 11%)
  • PAT Margin: 11% vs 11% in Q4FY24
  • Diluted EPS: Rs 6.30 vs Rs 5.70 in Q4FY24 (Change: 11%)

FY25 Financial Highlights:

  • Revenue from Operations: Rs 7,172 million vs Rs 6,196 million in FY24 (Change: 16%)
  • Other Income: Rs 255 million vs Rs 168 million in FY24
  • Total Income: Rs 7,427 million vs Rs 6,364 million in FY24 (Change: 17%)
  • EBITDA: Rs 1,958 million vs Rs 1,466 million in FY24 (Change: 34%)
  • EBITDA Margin: 27% vs 24% in FY24
  • EBIT: Rs 1,273 million vs Rs 865 million in FY24 (Change: 47%)
  • EBIT Margin: 17% vs 14% in FY24
  • Profit After Tax (PAT): Rs 776 million vs Rs 568 million in FY24 (Change: 37%)
  • PAT Margin: 11% vs 9% in FY24
  • Diluted EPS: Rs 23.56 vs Rs 17.31 in FY24 (Change: 36%)

Yash Mutha, Managing Director, said: “We are pleased to report the strongest Profit After Tax (PAT) growth since our listing, with PAT reaching Rs 776 million in FY25 a 37% YoY increase. This exceptional performance was driven by higher volumes and improved operational efficiency.

Krsnaa is executing several strategic initiatives to diversify its revenue streams beyond its current B2G-focused model. As part of our transition to an asset-light business model, we have entered into strategic partnerships with Medikabazaar and United Imaging to procure over 30 imaging machines on a deferred payment basis. We are also expanding into high-end PET-CT (oncology care) services through investments in Apulki Healthcare. Additionally, we are leveraging the Krsnaa brand at PPP centres to penetrate the B2C market. These initiatives will drive sustained growth, improve realizations, and reduce capex intensity, thereby enhancing the return ratios of the business.

Krsnaa has delivered impressive growth over the last five years and is well-positioned for continued growth. Our unique business model targets the underserved markets in tier 2–3 cities, offering significant volume growth potential, especially as more states adopt the PPP model for free diagnostic schemes. Our nationwide offerings in pathology and radiology mitigate concentration risk and create economies of scale.

In FY25, Krsnaa achieved a remarkable 16% year-on-year revenue growth, reaching Rs 7,172 million. Increased awareness of our high-quality services, combined with competitive pricing, has led to a significant rise in patient volumes and test counts. On the financial front, EBITDA surged 34% YoY to Rs 1,958 million, with improved margins of 27%. Net profit rose 37% YoY to Rs 776 million, with net margins at 11%, reflecting our ongoing commitment to operational efficiency through strategic initiatives. We remain confident in sustaining this positive momentum in the quarters ahead.

Looking forward, our senior management is fully committed to executing our growth strategies. We are actively expanding our participation in tenders and strengthening our pipeline to ensure sustained growth. With a clear vision and disciplined execution, we are poised to further solidify our market leadership.”

Pallavi Bhatevara, Executive Director, said: “At Krsnaa Diagnostics Limited, we leverage the Public-Private Partnership (PPP) model to provide free diagnostic services across India, with a strong pan-India presence. We have established ourselves as a key player in delivering high-quality and affordable diagnostic services, which are essential for disease diagnosis, management, and prevention. These services form a fundamental pillar of the healthcare industry.

The Indian diagnostics industry, historically fragmented with a network of unorganized players, has experienced steady growth. The market registered an 8% CAGR over the past five years, reaching approximately US$ 12 billion in FY24. Within this context, the organized segment, consisting of national and regional diagnostic chains, has outpaced the broader market, achieving a 12% CAGR. This makes diagnostics one of the fastest-growing segments in the Indian healthcare sector. However, despite this steady expansion, diagnostics penetration in India remains among the lowest globally, even when compared to other developing nations.

Krsnaa's Free Diagnostics Services has already made significant strides. To date, 12 states and Union Territories (UTs) have adopted free pathology services through the PPP model, and 19 states/UTs have adopted free radiology services, highlighting substantial untapped potential. State-level allocations for diagnostics have grown at an 18% CAGR, significantly outpacing the broader industry growth rate.

Krsnaa has effectively capitalized on these opportunities, securing pathology tenders in 8 out of 12 states and winning radiology tenders in 12 out of 19 states, resulting in an impressive 75% win-to-bid ratio. This strong performance positions Krsnaa Diagnostics as the leading PPP player, offering a fully integrated service portfolio across radiology, pathology, and teleradiology.”

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q3FY25 results

  • Revenue: Rs 1,745 million compared to Rs 1,583 million during Q3FY24, change 10%.
  • EBITDA: Rs 466 million compared to Rs 378 million during Q3FY24, change 23%.
  • PAT: Rs 194 million compared to Rs 130 million during Q3FY24, change 50%.
  • EPS: Rs 5.88 for Q3FY25.

Yash Mutha, Joint Managing Director, said: “We are pleased to report another strong quarter, driven by significant margin improvements, reflecting the success of our operational efficiency initiatives. I am delighted to share that your company has achieved a remarkable profit of Rs 569 million in 9MFY24, equaling the full-year profit of the previous year. We have successfully launched retail operations in four states, witnessing encouraging traction for our services.

In a major strategic milestone, we have placed a purchase order for machinery under our exclusive partnership with United Imaging and Medikabazaar. This unique arrangement, available only to Krsnaa, allows us to pay 10% upfront while spreading the remaining cost over six years—optimizing cash flow and enabling business expansion without additional strain on our balance sheet. This expansion aligns with our mission to provide accessible, affordable, and accurate diagnostics across both urban and rural regions. We remain committed to sustainable, profitable growth by leveraging our core strengths, optimizing cost structures, and investing in high-growth opportunities.

In the first nine months of FY25, Krsnaa achieved an impressive 17% year-on-year revenue growth, reaching Rs 5,311 million. Increased awareness of our high-quality service offerings, combined with competitive pricing, has significantly boosted patient volumes and test counts. On the financial front, EBITDA surged 39% YoY to Rs 1,416 million, with margins improving to 27%. Net profit rose 49% YoY to Rs 569 million, with net margins at 11%—demonstrating our continued focus on operational efficiency through strategic initiatives. We are confident in maintaining this positive trajectory in the coming quarters.

Looking ahead, our senior management remains fully committed to executing our core growth strategies. We are actively expanding our participation in tenders and strengthening our pipeline for sustained growth. With a clear vision and disciplined execution, we can further solidify our market leadership.”

Pallavi Bhatevara, Executive Director, said: “Krsnaa Diagnostics Limited has been a key player in delivering high-quality and affordable diagnostic services, essential for disease diagnosis, management, and prevention. The provision of these services is a fundamental pillar of the healthcare industry.

At Krsnaa, we firmly believe that our employees are the backbone of our success, and we are committed to fostering a work environment that prioritizes their well-being, growth, and professional development. As part of this commitment, we have launched several initiatives aimed at enhancing employee engagement, upskilling, and overall job satisfaction. We have introduced comprehensive training programs designed to equip our workforce with the latest advancements in diagnostic technology, ensuring they remain at the forefront of industry standards.

As we continue to grow, we remain dedicated to investing in our people, ensuring they have the right tools, knowledge, and support to thrive. A well-trained and motivated workforce is key to our mission of providing accessible, affordable, and accurate diagnostics to communities across the country.

The recent contract wins highlight the exceptional capabilities of our in-house teams, showcasing their proficiency in navigating the complex bidding process, meeting all requirements, and successfully securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, laying a strong foundation for sustainable, long-term growth.”

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q1FY25 results:

Financial Highlights: 

  • Revenue from Operations: Rs 1,702 million in Q1FY25, a 22% increase compared to Rs 1,396 million in Q1FY24 and a 2% increase from Rs 1,663 million in Q4FY24.
  • Other Income: Rs 73 million in Q1FY25, showing a 43% increase compared to Rs 42 million in Q1FY24.
  • Total Income: Rs 1,775 million in Q1FY25, a 23% increase from Rs 1,438 million in Q1FY24 and a 4% increase from Rs 1,706 million in Q4FY24.
  • EBITDA: Rs 442 million in Q1FY25, a 39% increase from Rs 319 million in Q1FY24, and virtually unchanged from Rs 445 million in Q4FY24.
  • EBITDA Margin: 26% in Q1FY25, up from 23% in Q1FY24 but down from 27% in Q4FY24.
  • EBIT: Rs 285 million in Q1FY25, a 44% increase compared to Rs 199 million in Q1FY24, and a 4% decrease from Rs 299 million in Q4FY24.
  • EBIT Margin: 16% in Q1FY25, improved from 14% in Q1FY24 but down from 18% in Q4FY24.
  • Profit After Tax (PAT): Rs 179 million in Q1FY25, representing a 24% increase from Rs 146 million in Q1FY24 and a 4% decrease from Rs 187 million in Q4FY24.
  • PAT Margin: 11% in Q1FY25, consistent with the margin in Q1FY24 and Q4FY24.
  • Reported Diluted EPS: Rs 5.46 in Q1FY25, compared to Rs 4.52 in Q1FY24 and Rs 5.70 in Q4FY24.

Operational Highlights:

  • Krsnaa has bagged the contract for Tele-Radiology from BARC
  • Krsnaa has signed an agreement for 5 MRIs to be installed in 5 districts of Madhya Pradesh
  • Krsnaa has Launched Krsnaa Retail Pvt. Ltd to focus on increasing their retail presence beginning with 5 states i.e. Maharashtra, Punjab, Odisha, Assam & Himachal Pradesh.
  • Krsnaa expanded its presence by establishing 395 new centers across the nation.

Commenting on the results, Yash Mutha, Joint Managing Director, said: “Krsnaa's exceptional service offerings, characterized by competitive pricing, have played a pivotal role in driving patient and test counts.

We are committed to enhancing the customer experience by offering exceptional healthcare solutions customized to individual needs. Krsnaa has established itself as a prominent player in the PPP sector and is one of the largest in the industry. Given the industry's growth and the next phase for our organization, we believe it is the right time to venture into the retail space. Our strategy is to offer a wide range of services to the general population, starting with states where we already have wellestablished lab and radiology centers through our PPP contracts. This approach will help us increase our margins and shorten our working capital cycle.

During the initial quarter of FY2025, Krsnaa accomplished a notable 22% increase compared to the previous year, leading to revenues totalling Rs. 1,702 million. Our EBIDTA reached Rs. 442 million with a 26% margin, and the net profit was Rs. 179 million with an 11% margin. This progress can be credited to our status as the government's preferred partner, heightened recognition of Krsnaa as a brand, maintaining high-quality services, and the successful and punctual execution of our projects.

We are also working on various other PAN India tenders, which will be announced once there is more clarity from the respective departments. At the gateway of boundless potential, we are unwavering in our commitment to adjust, create, and thrive. We have developed ambitious strategies to discover chances for progress and development, guaranteeing that we persist in positively influencing lives and contributing to the advancement of the healthcare sector.”

Commenting on the Business, Pallavi Bhatevara, Executive Director said: “Our company is well positioned to take advantage of the changes in the diagnostic industry, especially with the government's emphasis on delivering high-quality healthcare to all citizens. The budget for the National Health Mission (NHM) for 2024-25 is set at Rs 38,183 crores, marking a significant rise from the revised allocation of Rs 33,886 crores in 2023-24.

Krsnaa diagnostics limited continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry. It is with great pleasure that I announce our successful execution of an agreement for the Madhya Pradesh Radiology tender, a significant opportunity that encompasses 5 MRI centre, along with these we have also bagged a contract for Tele-radiology from BARC. These showcase our capabilities and strength to grow in diagnostic industry.

Currently, Krsnaa Diagnostics is well-equipped to deploy 28 CT scan machines, 24 MRI machines, establish 153 labs, and set up 2,291 collection centers, all under various contractual agreements. The recent contract wins highlight the exceptional capabilities of our in-house teams. It reflects their proficiency in navigating the intricate bidding process, meeting all necessary requirements, and ultimately securing these contracts. As we begin these projects, Krsnaa Diagnostics is actively expanding its presence into new geographical regions, laying a strong foundation for sustainable, long-term growth.”

Result PDF

Healthcare Services company Krsnaa Diagnostics announced FY24 results:

  • Revenue from Operations: Rs 6,196 million, up 27% YoY
  • EBITDA: Rs 1,461 million, representing an 18% YoY growth with a 24% margin
  • Profit After Tax: Rs 568 million

Commenting on the business, Yash Mutha, Joint Managing Director, said: “I am pleased to announce the outstanding results for the quarter and financial year 2024 which align with our strategic growth plans. Krsnaa Diagnostics is uniquely positioned to capitalize on the burgeoning growth trends in diagnostics Industry.

We are thrilled to announce a historic milestone in India: Krsnaa Diagnostics is the first ever lab operating in a government location to receive the prestigious CAP accreditation, setting a new benchmark for excellence in the industry. The CAP accreditation is a testament to our commitment to quality and excellence in diagnostic services.

We have recently secured a significant agreement with the Maharashtra Government for the installation and operation of 17 MRI and 17 CT machines, which is India’s one of the largest MRI tenders and further cements our leadership in the industry. We are excited to welcome Mr. Mitesh Dave as Group CEO, with him at helm we are poised to accelerate our penetration into the B2C market. We are confident that under Mitesh’s leadership, Krsnaa Diagnostics will continue to set new benchmarks in the diagnostics industry, delivering exceptional value to our stakeholders and enhancing our market position.”

Commenting on the business, Pallavi Bhatevara, Executive Director, said: “Indian Healthcare ecosystem stands to benefit from structural tailwinds like increased consumer awareness, favorable demographics, rise in lifestyle related diseases, and strong thrust towards infrastructure from the public sector. India’s healthcare expenditure - only 3% of GDP has historically remained suppressed vs. global peers owing to higher ‘out of pocket’ expenses and lower health insurance penetration.

Krsnaa Diagnostics continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry.

At present, Krsnaa Diagnostics is well-positioned to deploy 67 CT Scan machine, 23 MRI machine, establish 162 labs and set up 3,153 collection centers, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all necessary requirements, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, establishing a solid foundation for sustainable, long-term growth.”

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q3FY24 & 9MFY24 results:

Q3FY24 Financial Highlights:

  • In Q3FY24, the core business generated a revenue of Rs 1,583 million, marking a significant 34% year-on-year growth from Rs 1,180 million in Q3FY23.
  • Revenue from operations for the core business in Q3FY24 stood at Rs 1,583 million, compared to Rs 1,181 million in Q3FY23.
  • Other income in Q3FY24 was Rs 41 million, slightly lower than the Rs 45 million reported in Q3FY23.
  • Total income in Q3FY24 reached Rs 1,624 million, compared to Rs 1,226 million in Q3FY23.
  • EBITDA for the core business in Q3FY24 was Rs 378 million, showing a substantial 27% increase from Rs 298 million in Q3FY23.
  • The EBITDA margin for the core business was 24% in Q3FY24, slightly lower than the 25% reported in Q3FY23.
  • EBIT for the core business in Q3FY24 amounted to Rs 202 million, similar to the Rs 200 million reported in Q3FY23.
  • The EBIT margin for the core business was 13% in Q3FY24, lower than the 17% reported in Q3FY23.
  • Profit after tax (PAT) for the core business in Q3FY24 was Rs 130 million, representing a 5% decrease from Rs 136 million in Q3FY23.
  • The PAT margin for the core business was 8% in Q3FY24, lower than the 12% reported in Q3FY23.
  • The reported diluted earnings per share (EPS) for the core business in Q3FY24 was Rs 3.97, compared to Rs 4.24 in Q3FY23.

9MFY24 Financial Highlights:

  • Core business revenue amounted to Rs 4,533 million, reflecting a robust 28% year-on-year growth from Rs 3,532 million in 9MFY23.
  • Revenue from operations totaled Rs 4,533 million, up from Rs 3,539 million in 9MFY23.
  • Other income amounted to Rs 125 million, down from Rs 135 million in 9MFY23.
  • Total income was Rs 4,658 million, up from Rs 3,674 million in 9MFY23.
  • EBITDA stood at Rs 1,020 million, compared to Rs 891 million in 9MFY23.
  • EBITDA margin was 23%, consistent with the margin in 9MFY23.
  • EBIT totaled Rs 566 million, down from Rs 621 million in 9MFY23.
  • EBIT margin was 12%, consistent with the margin in 9MFY23.
  • PAT amounted to Rs 381 million, down from Rs 432 million in 9MFY23.
  • PAT margin was 8%, down from 12% in 9MFY23.
  • Over the nine months of FY24, the reported diluted EPS was Rs 11.71, down from Rs 13.42 in 9MFY23.

Operational Highlights for Q3FY24:

  • Krsnaa has been short-listed to provide 17 MRI and 17 CT scan services in Maharashtra.
  • Krsnaa has been shortlisted to provide MRI services in 5 Districts in Madhya Pradesh.
  • Bagged contract to provide HPLC test at 21 districts in Maharashtra.
  • Krsnaa has operationalized the pathology project in Assam.
  • Krsnaa expanded its presence by establishing 195 new centers across the nation.

Commenting on the Business, Pallavi Bhatevara, Managing Director, said: "We are one of the leaders benefiting from the transformation in the diagnostic industry, with the government's focus on providing the best healthcare facilities to all. In the Interim budget, there has been a focus on increasing the number of medical colleges pan India and including ASHA workers and Anganwadi Workers and helpers in the Ayushman Bharat Scheme. These policy measures would bring more people under the fold of public healthcare.

Krsnaa Diagnostics Limited continues to play a major role in providing high-quality and affordable diagnostic services. The provision of high-quality and affordable diagnostic services stands as a fundamental pillar within the healthcare industry.

It is with great pleasure that I announce our successful execution of an agreement for the Assam Pathology tender, a significant opportunity that encompasses 10 Labs and 1,256 collection centers. This development significantly enhances our presence, covering all districts of Assam.

At present, Krsnaa Diagnostics is well-positioned to deploy 54 CT Scan machines, and 24 MRI machines, establish 156 labs, and set up 2,768 collection centers, all under various contractual agreements. These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their proficiency in navigating the intricate bidding process, meeting all requirements, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, establishing a solid foundation for sustainable, long-term growth."

Result PDF

Healthcare Services company Krsnaa Diagnostics announced Q1FY24 results:

  • Total Income of Rs 1,438 million in Q1FY24 compared to Rs 1,175 million in Q1FY23, up 22% YoY
  • EBITDA of Rs 319 million in Q1FY24 compared to Rs 283 million in Q1FY23, up 13% YoY
  • EBITDA Margin of 23% in Q1FY24 compared to 25% in Q1FY23
  • Profit After Tax of Rs 146 million in Q1FY24 compared to Rs 142 million in Q1FY23, up 3% YoY
  • Reported Diluted EPS of Rs 4.52 in Q1FY24 compared to Rs 4.51 in Q1FY23
  • Net Cash position of Rs 2,246 million
  • Receivable days decline from 86 days in Q1FY23 to 79 days in Q1FY24
  • Krsnaa won the tender in Assam for the establishment of 10 laboratories and 1,256 collection centres spanning all districts in Assam.
  • Krsnaa expanded its presence by establishing 97 new centres across the nation.

Commenting on the Business, Pallavi Bhatevara, Managing Director, said, “Addressing the initial challenges encountered in the new fiscal year, I am pleased to share a positive turn of events. The esteemed High Court of Rajasthan has ruled in favor of Krsnaa Diagnostics and TCIL, directing both entities to meet the stipulated conditions regarding additional performance security. In line with this judgment, the Authorities are also willing to go ahead with the Agreement and execute the project and no contest remains between the parties.

Furthermore, I am delighted to announce we have recently executed an agreement for the Assam pathology tender, a significant opportunity encompassing 10 Labs and 1,256 collection centres. This strengthens our widespread presence across all districts of Assam.

Presently, Krsnaa Diagnostics is poised to deploy 51 CT scan units, and 2 MRI machines, establish 168 labs, and set up 3,705 collection centres, all under various contractual agreements.

These recent contract wins underscore the exceptional capabilities of our in-house teams, reflecting their adeptness in navigating the intricate bidding process, meeting prerequisites, and ultimately securing these contracts. As we embark on these projects, Krsnaa Diagnostics continues to expand its footprint into new geographical regions, establishing a robust foundation for sustainable, long-term growth.”

 

 

 

Result PDF

Healthcare Services company Krsnaa Diagnostics announced FY23 results:

  • Revenue from Operations registered a Revenue of Rs 4,871 million, an increase of 7.0% on a YoY basis
  • EBITDA of Rs 1,240 million, with Margins of 25.4%
  • Profit After Tax of Rs 621 million, with margins of 12.8%
  • Core business of Radiology and Pathology registered a Revenue of Rs 4,864 million, an increase of 14.8% on a YoY basis and Covid-19 Revenues decreased by 97.8% to Rs 7 million
  • Cash Generated from Operating Activities Before Tax of Rs 89 crore
  • Net Cash position of Rs 272 crore as of 31st March 2023
  • The Board of Directors has recommended a dividend of Rs 2.75 per share, 55% of the Face Value

Commenting on the Business, Pallavi Bhatevara, Managing Director, said: “Krsnaa Diagnostics has firmly established itself as the leading provider of premium quality integrated diagnostic services in India, with a robust network spanning over 2,850 locations. Our primary focus remains on addressing the healthcare needs of our society by ensuring accessibility and affordability of our services. As part of our growth strategy, we successfully operationalized 26 radiology centers, 50 pathology labs, and 556 collection centers during FY2023, further expanding our reach and service offerings.

We are immensely proud to share that our Teleradiology hub in Pune has achieved accreditation from the prestigious NABH. This recognition is a significant milestone in the history of Indian healthcare, making our teleradiology hub the 1 st to receive such esteemed accreditation from NABH. This accreditation serves as a testament to our unwavering commitment to delivering high-quality healthcare services by embracing cutting-edge technologies.

Furthermore, we have achieved notable success in last twelve months by securing nine tenders across various states. All these projects encompass 53 CT and MRI centres,158 Pathology labs, and 2,281 Pathology collection centers substantially strengthening our growth prospects for the future.

Looking ahead, we are excited about the upcoming operationalization of these projects, as they present substantial growth opportunities for us. These projects will enable us to strengthen our presence, reach more customers, and create new growth paths in these regions. We remain dedicated to delivering exceptional services and maximizing our impact as we continue to expand our footprint across the country.”

 

Result PDF

Healthcare service company Krsnaa Diagnostics announced Q2FY23 results:

  • Revenue from operations was Rs 2,358 million
  • The core business of radiology and pathology registered a revenue of Rs 2,352 million, an increase of 14.7% YoY 
  • Covid-19 revenues decreased by 98.4% to Rs 6 million
  • EBITDA of Rs 593 million, with Margins of 25.1%
  • Profit After Tax of Rs 296 million, with margins of 12.5%

Pallavi Bhatevara, Managing Director, said: “Krsnaa Diagnostics has always been at the forefront of serving the healthcare needs of our society. Today, the company is the largest premium quality integrated diagnostics service provider in India with 2,000 locations with accessible and affordable rates. In line with our growth strategy, Krsnaa Diagnostic has operationalised 10 pathology labs out of 24 and 126 collection centres out of 190 in Himachal Pradesh. In Punjab, the company has operationalised 20 CT scanners out of 25, five MRI machines out of six, and 18 pathology labs out of 30, including one referral laboratory and 95 collection centres. This amounts to the completion of 88% of the project as of date.

Considering the rising demand for diagnostics services and to cater to the remotest parts of the country, Krsnaa Diagnostics has entered selected markets through the franchise and in addition plan to launch 600 collection centres across India, providing services at attractive prices. This growth will strengthen the company’s footprint across Maharashtra, Himachal Pradesh, Punjab, West Bengal, and Rajasthan, especially in tier 2 and 3 cities. The centres are well-equipped to offer specialised services in genetics, genomics and molecular diagnostics, along with the core investigations of biochemistry, serology and histopathology. The centres will provide dedicated services for women’s health (hormones/ PCOD), diabetes monitoring, cardiac health and cancer care. With continued expansion to new geographies and diversification, Krsnaa continues to build its strong fundamentals for long term.”

Result PDF

Trending News

Midhani has secured an order of Rs. 121.75 crore

Midhani has secured an order of Rs. 121.75 crore

Published on 19-Dec-2025 09:02

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Aeroflex Industries Board has approved a ₹97.56 crore expansion plan

Published on 19-Dec-2025 09:01

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

As per media sources, HDFC Bank has raised a $1 billion three-year overseas loan from its GIFT City branch

Published on 19-Dec-2025 09:00

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

TCS, on its Investor Day 2025, articulated a clear shift towards an AI-first enterprise

Published on 18-Dec-2025 09:07

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Syrma SGS Technology has completed the first tranche of its acquisition of defence and aerospace electronics firm Elcome Integrated Systems

Published on 18-Dec-2025 09:06

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

POWERGRID has commissioned the Western Region Expansion Scheme-XXV

Published on 18-Dec-2025 09:05

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status